Evommune (EVMN) Other financing activities (2024 - 2026)
Evommune (EVMN) posted quarterly Other financing activities of $157.3 million for Q4 2025, up 1429700.0% year-over-year from N/an in Q4 2024, and up 1429700.0% quarter-over-quarter from $11000.0 in Q4 2024.
Powered by 
Analysis
Evommune (EVMN) Other financing activities (2024 - 2026) Analysis & Trends
Evommune (EVMN) has reported Other financing activities for 2 consecutive years, with $157.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Other financing activities rose 1429700.0% year-over-year to $157.3 million; the TTM figure through Mar 2026 stood at $157.3 million (changed N/A YoY), while the FY2025 annual figure was $157.3 million, up 1209776.92% from the prior year.
- Other financing activities rose to $157.3 million in Q4 2025 per EVMN's latest filing, from $11000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $157.3 million in Q4 2025 and bottomed at $11000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Evommune | 445.19 Mn | 244.40 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -58,000.00 |
| Mar 31, 2026 | 117.20 Mn |
| Dec 31, 2025 | 156.41 Mn |
| Sep 30, 2025 | 138,000.00 |
| Jun 30, 2025 | 734,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Dec 31, 2024 | 11,000.00 |